drugset / Trial / NCT00676130

Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients

NCT00676130

Completed 153 enrolled Brigham and Women's Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary aim of this study is to quantify the effectiveness of Bactrim as additional therapy for the treatment of uncomplicated cellulitis in adults, by comparing: standard therapy plus Bactrim, versus standard therapy plus placebo. The primary hypothesis of this study is that, in light of increasing CA-MRSA prevalence, subjects treated with standard therapy plus Bactrim will have higher cure rates than those treated with standard therapy plus placebo.

Timeline

Start
2007-05
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject trimethoprim-sulfamethoxazole Unknown 40 mg
Subject trimethoprim-sulfamethoxazole Unknown 60 mg
Subject trimethoprim-sulfamethoxazole Unknown 72 mg
Subject trimethoprim-sulfamethoxazole Unknown 80 mg
Subject trimethoprim-sulfamethoxazole Unknown 160 mg
Background CEPHALEXIN ANHYDROUS Small molecule 300 mg
Background CEPHALEXIN ANHYDROUS Small molecule 400 mg
Background CEPHALEXIN ANHYDROUS Small molecule 500 mg
Background CEPHALEXIN ANHYDROUS Small molecule 1000 mg

Indications